DDX60 Inhibitors

DDX60 inhibitors encompass a range of chemical entities that indirectly affect the function of the DDX60 protein by modulating various pathways and cellular processes. These inhibitors include nucleoside analogs like 2'-C-Methylcytidine and Ribavirin, which can interfere with viral RNA synthesis and processing-a key area of DDX60 activity. By altering the availability of RNA substrates, these compounds can modulate the functional engagement of DDX60 with viral RNA.

Other inhibitors target signaling pathways that are linked to DDX60's role in the innate immune response. For example, JAK Inhibitor I can modulate cytokine signaling, which in turn could influence DDX60's involvement in antiviral responses. TLR7 and TLR3 antagonists specifically target receptors that recognize viral RNA, which are upstream of DDX60's implicated pathways, and their inhibition can affect the subsequent immune signaling cascade. BX795 and Amlexanox inhibit TBK1 and IKK-ε, key kinases in the interferon signaling pathway which are thought to be connected to DDX60's function in immune response regulation. Chloroquine disrupts endosomal and lysosomal pH, which can affect the trafficking or stability of DDX60 within the cell. PI3K inhibitor LY294002 can influence the Akt signaling pathway, thereby affecting a broad range of cellular processes including those associated with DDX60 function. Auranofin impacts the cellular redox state, which can have downstream effects on various proteins including DDX60. Lastly, Rapamycin, an mTOR inhibitor, affects cellular growth and metabolism, which could indirectly influence DDX60's role in the cell.